While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ...

In Q4, Dupixent grew by 16% from strong prescription ... of Inhibrx as well as our value proposition to shareholders in the form of a growing dividend. Our net debt-to-EBITDA ratio, which is ...

We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

Dupixent (dupilumab) is tipped to be the market ... The potential AD market in Europe is very large: the most common form of eczema, around 1.5 million adults in the UK alone have the condition.

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra (benralizumab) - which ...

It may cause side effects similar to those of Dupixent. Phototherapy, or light therapy, involves treatment with different wavelengths of ultraviolet light. The most common form doctors recommend ...